Status:
NOT_YET_RECRUITING
Effects of Emicizumab Treatment in Patients With Hemophilia A
Lead Sponsor:
Hasan Kalyoncu University
Conditions:
Hemophilia A
Musculoskeletal Assessment
Eligibility:
MALE
1-18 years
Brief Summary
The aim of our study is to investigate the effects of emicizumab treatment on the musculoskeletal system in children with hemophilia A.
Detailed Description
Hemophilia is a rare inherited coagulation disorder resulting from a deficiency of factor (F) VIII or IX. It is a chronic group of diseases that primarily manifests as intra-articular (hemarthrosis) a...
Eligibility Criteria
Inclusion
- Children who are under 18 years of age,
- Have been diagnosed with Hemophilia A by a physician,
- Have a factor level of 1% (IU) or less,
- Have inhibitors positive or negative,
- Have no obstacles to starting subcutaneous (emicizumab) treatment,
- Willing to participate in the study
Exclusion
- \- Children with a history of cerebrovascular bleeding who present any neurological findings that would prevent participation in the study
Key Trial Info
Start Date :
September 30 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 10 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT07190118
Start Date
September 30 2025
End Date
February 10 2026
Last Update
September 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hasan Kalyoncu University
Gaziantep, Gaziantep, Turkey (Türkiye), (505) 090-5846